#Bmtsm

Is Autologous HCT in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era? Question examined by @CIBMTR @niravshahmd @timfenske#bmtsm #lymsm (1/6)https://pubmed.ncbi.nlm.nih.gov/33120429/  249 PET+ DLBCL p
Read more
What happens to hematopoietic transplant recipients who develop #COVID19? Transplant recipients and transplanters have been asking this question ever since the pandemic began. Our analysis using @CIBMTR data is out
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.